Trial Profile
A Study Assessing the Clinical Efficacy of Icotinib in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 18 E709X Mutations.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2017
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.